Protein kinases, their function and implication in cancer and other diseases

Folia Biologica

Volumn 52, Issue 3, 2006, Pages 81-101

  Shchemelinin, Igor ^a   Sefc L ^a   Necas E ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cancer therapy; Protein kinase; Protein phosphorylation

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AURORA A KINASE; AURORA B KINASE; B RAF KINASE; BCR ABL PROTEIN; BUB1 RELATED PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FIBROBLAST GROWTH FACTOR 1; FLT3 LIGAND; GENISTEIN; IMATINIB; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; POLO LIKE KINASE; PROTEIN KINASE; PROTEIN KINASE C; PROTEIN RET; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; RHO KINASE; STEM CELL FACTOR RECEPTOR; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR;

ALZHEIMER DISEASE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHOSPHORYLATION; CANCER; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CELL CYCLE PROGRESSION; CELL DIVISION; CELL METABOLISM; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME STRUCTURE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENE OVEREXPRESSION; GENETIC CODE; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMOGENESIS; LYMPH NODE METASTASIS; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE; PARKINSON DISEASE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SARCOMA; SIGNAL TRANSDUCTION;

EID: 33747625153     PISSN: 00155500     EISSN: 25337602     Source Type: Journal    
DOI: None     Document Type: Review

References (144)

1. Alitalo, K., Carmeliet, P. (2002). Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1, 219-227.
2. Amano, M., Kaneko, T., Maeda, A., Nakayama, M., Ito, M., Yamauchi, T., Goto, H., Fukata, Y., Oshiro, N., Shinohara, A., Iwamatsu, A., Kaibuchi, K. (2003) Identification of Tau and MAP2 as novel substrates of Rho-kinase and myosin phosphatase. J. Neurochem. 87, 780-790.
3. Arimura, N., Inagaki, N., Chihara, K., Menager, C., Nakamura, N., Amano, M., Iwamatsu, A., Goshima, Y., Kaibuchi, K. (2000) Phosphorylation of collapsin response mediator protein-2 by Rho-kinase. Evidence for two separate signaling pathways for growth cone collapse. J. Biol. Chem. 275, 23973-23980.
4. Banchio, C., Schang, L. M., Vance, D. E. (2004) Phosphorylation of Sp1 by cyclin-dependent kinase 2 modulates the role of Sp1 in CTP: phosphocholine cytidilyl transferase alpha regulation during the S phase of the cell cycle. J. Biol. Chem 279, 40220-40226.
5. Barlesi, F., Tchouhadjian, C., Doddoli, C., Villani, P., Greillier, G., Kleisbauer, J. P., Thomas, P., Astoul, P. (2005) Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective. Fundam. Clin. Pharmacol. 19, 385-393.
6. Barnhill, R. L., Xiao, M., Graves, D. Antoniades, H. N. (1996) Expression of platelet-derived growth factor (PDGF)-A, PDFG-B and the PDGF-alpha receptor, but not the PDGF-beta receptor, in human malignant melanoma in vivo. Br. J. Dermatol. 135, 898-904.
7. Belloni, E., Trubia, M., Gasparini, P., Micucci, C., Tapinassi, C., Confalonieri, S., Nuciforo, P., Martino, B., Lo-Coco, F., Pelicci, P. G., Di Fiore, P. P. (2005) 8p11 myeloproliferative syndrome with a novel t(7; 8) translocation leading to fusion of the FGFR1 and TIF1 genes. Genes Chromosomes Cancer 42, 320-325.
8. Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., Hanahan, D. (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111, 1287-1295.
9. Bischoff, J. R., Anderson, L., Zhu, Y., Mossie, K., Ng, L., Souza, B., Schryver, B., Flanagan, P., Clairvoyant, F., Ginther, C., Chan, C. S., Novotny, M., Slamon, D. J., Plowman, G. D. (1998) A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 17, 3052-3065.
10. Blagden, S., de Bono, J. (2005) Drugging cell cycle kinases in cancer therapy. Curr. Drug Targets 6, 325-335.
11. Borie, D. C., O'Shea, J. J., Changelian, P. S. (2004) JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants. Trends Mol. Med. 10, 532-541.
12. Bowers, A. J., Boylan, J. F. (2004) Nek8, a NIMA family kinase member, is overexpressed in primary human breast tumors. Gene 328, 135-142.
13. Breier, G., Risau, W. (1996) The role of vascular endothelial growth factor in blood vessel formation. TIBC 6, 454-456.
14. Buchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Drucker, B. J., Lydon, N. B. (2000) Ab1 protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295, 139-145.
15. Chang, L., Jones, Y., Ellisman, M. H., Goldstein, L. S., Karin, M. (2003) JNK1 is required for maintenance of neuronal microtubules and controls phosphorylation of microtubule-associated proteins. Dev. Cell 4, 521-533.
16. Cheetham, G. M. (2004) Novel protein kinases and molecular mechanisms of autoinhibition. Curr. Opin. Struct. Biol. 14, 700-705.
17. Chen, Y., Sanchez, Y. (2004) Chk1 in the DNA damage response: conserved roles from yeasts to mammals. DNA Repair (Amst.) 3, 1025-1032.
18. Cicchetti, P., Mayer, B. J., Thiel, G., Baltimore, D. (1992) Identification of a protein that binds to the SH3 region of Ab1 and is similar to Bcr and GAP-rho. Science 257, 803-806.
19. Coffey, E. T., Smiciene, G., Hongisto, V., Cao, J., Brecht, S., Herdegen, T., Courtney, M. J. (2002) c-Jun N-terminal protein kinase (JNK) 2/3 is specifically activated by stress, mediating c-Jun activation, in the presence of constitutive JNK1 activity in cerebellar neurons. J. Neurosci. 22, 4335-4345.
20. Cohen, P. (2002) Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1, 309-315.
21. Colucci, F., Di Santo, J. P. (2000) The receptor tyrosine kinase c-kit provides a critical signal for survival, expansion, and maturation of mouse natural killer cells. Blood 95, 984-991.
22. Conn, C. W., Hennigan, R. F., Dai, W., Sanchez, Y., Stambrook, P. J. (2000) Incomplete cytokinesis and induction of apoptosis by overexpression of the mammalian polo-like kinase, Plk3. Cancer Res. 60, 6826-6831.
23. Corless, C. L., Schroeder, A., Griffith, D., Town, A., McGreevey, L., Harrell, P., Shiraga, S., Bainbridge, T., Morich, J., Heinrich, M. C. (2005) PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J. Clin. Oncol. 23, 5357-5364.
24. d'Auriol, L., Mattei, M. G., Andre, C., Galibert, F. (1988) Localization of the human c-kit protooncogene on the q11-q12 region of chromosome 4. Hum. Genet. 78, 374-376.
25. Daley, G. Q., Baltimore, D. (1992) Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein, Proc. Natl. Acad Sci. USA 85, 9312-9316.
26. Davis, M. J., Wu, X., Nurkiewicz, T. R., Kawasaki, J., Gui, P., Hill, M. A., Wilson, E. (2001) Regulation of ion channels by protein tyrosine phosphorylation. Am. J. Physiol. Heart Circ. Physiol. 281, H1835-H1862.
27. de Bono, J. S., Tolcher, A. W., Rowinsky, E. K. (2003) Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma. Semin. Oncol. 30 (Suppl. 16), 79-92.
28. de Mestie, P., des Guetz, G. (2005) Treatment of gastrointestinal stromal tumors with imatinib mesylate: a major breakthrough in the understanding of tumor-specific molecular characteristics. World J. Surg. 29, 357-361.
29. Deininger, M. W. (2004) Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia. J. Cancer Res. Clin. Oncol. 130, 59-72.
30. Deininger, M. W., Goldman, J. M., Melo, J. V. (2000) The molecular biology of chronic myeloid leukemia. Blood 96, 3343-3356.
31. Dewji, M. R. (2004) Early phase I data on an irreversible panerb inhibitor: CI-1033. What did we learn? J. Chemother. 16 (Suppl. 4), 44-48.
32. Duensing, A., Joseph, N. E., Medeiros, F., Smith, F., Hornick, J. L., Heinrich, M. C., Corless, C. L., Demetri, G. D., Fletcher, C. D., Fletcher, J. A. (2001) Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res. 64, 5127-5131.
33. Duensing, A., Medeiros, F., McConarty, B., Joseph, N. E., Panigrahy, D., Singer, S., Fletcher, C. D., Demetri, G. D., Fletcher, J. A. (2004) Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 23, 3999-4006.
34. Engh, R. A., Bossemeyer, D. (2002) Structural aspects of protein kinase control - role of conformational flexibility. Pharmacol. Ther. 93, 99-111.
35. Fehm, T., Jager, W., Kramer, S., Sohn, C., Solomayer, E., Wallwiener, D., Gebauer, G. (2004) Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer. Anticancer Res. 24 (3b), 1987-1992.
36. Fisk, H. A., Mattison, C. P., Winey, M. (2004) A field guide to the Mps1 family of protein kinases. Cell Cycle 3, 439-442.
37. Geissler, E. N., Ryan, M. A., Housman, D. E. (1988) The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 55, 185-192.
38. Gordon, D. (1992) Growth factors and cell proliferation in human transplant arteriosclerosis. J. Heart Lung Transplant. 11, S7.
39. Griffin, J. H., Leung, J., Bruner, R. J., Caligiuri, M. A., Briesewitz, R. (2003) Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc. Natl. Acad. Sci. USA 100, 7830-7835.
40. Gu, T. L., Tothova, Z., Scheijen, B., Griffin, J. D., Gilliland, D. G., Sternberg, D. W. (2004) NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. Blood 103, 4622-4629.
41. Habedanck, R., Stierhof, Y. D., Wilkinson, C. J., Nigg, E. A. (2005) The Polo kinase Plk4 functions in centriole duplication. Nat. Cell Biol. 7, 1140-1146.
42. Hallek, M., Danhauser-Riedl, S., Herbst, R., Warmuth, M., Winkler, A., Kolb, H. J., Druker, B., Griffin, J. D., Emmerich, B., Ullrich, A. (1996) Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells. Br. J. Haematol. 94, 5-16.
43. Hantschel, O., Nagar B., Guettler S., Kretzschmar J., Dorey, K., Superti-Furga, G. (2003) A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 112, 845-857.
44. Harvey, R. D. (2004) Regulation of cardiac Na-Ca exchange activity by selective tyrosine kinase inhibition. Br. J. Pharmacol. 143, 929-930.
45. Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., von Mehren, M., Joensuu, H., McGreevey, L. S., Chen, C. J., Van den Abbeele, A. D., Druker, B. J., Kiese, B., Eisenberg, B., Roberts, P. J., Singer, S., Fletcher, C. D., Silberman, S., Dimitrijevic, S., Fletcher, J. A. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21, 4342-4349.
46. Heldin, C. H. (1995) Dimerization of cell surface receptors in signal transduction. Cell 80, 213-223.
47. Hermanson, M., Funa, K., Hartman, M., Claesson-Welsh, L., Heldin, C. H., Westermark, B., Nister, M. (1992) Platelet-derived growth factor and its receptors in human glioma tissue: Expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. 52, 3213-3219.
48. Hirosumi, J., Tuncman, G., Chang, L., Gorgun, C. Z., Uysal, K. T., Maeda, K., Karin, M., Hotamisligil, G. S. (2002) A central role for JNK in obesity and insulin resistance. Nature 420, 333-336.
49. Holyoak, T. L. (2001) Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory. Br. J. Haematol. 113, 11-23.
50. Hubbard, S. R. (2004) Juxtamembrane autoinhibition in receptor tyrosine kinases. Nat. Rev. Mol. Cell Biol. 5, 464-471.
51. Jenny, M., Wrulich, O. A., Schwaige, W., Ueberall, F. (2005) Relevance of atypical protein kinase C isotypes to the drug discovery process. Chembiochem. 6, 491-499.
52. Johnson, G. L., Dohlman, H. G., Graves, L. M. (2005) MAPK kinase kinases (MKKKs) as a target class for small-molecule inhibition to modulate signaling networks and gene expression. Curr. Opin. Chem. Biol. 9, 325-331.
53. Johnson, L. N., De Moliner, E., Brown, N. R., Song, H., Barford, D., Endicott, J. A., Noble, M. E. (2002) Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2. Pharmacol. Ther. 93, 113-124.
54. Jones, A. V., Cross, N. C. (2004) Oncogenic derivatives of platelet-derived growth factor receptors. Cell Mol. Life Sci. 61, 2912-2923.
55. Kaldis, P., Russo, A. A., Chou, H. S., Pavletich, N. P., Solomon, M. J. (1998) Human and yeast cdk-activating kinases (CAKs) display distinct substrate specificities. Mol. Biol. Cell 9, 2545-2560.
56. Katayama, H., Brinkley, W. R., Sen, S. (2003) The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev. 22, 451-464.
57. Kesari, S., Ramakrishna, N., Sauvageot, C., Stiles, C. D., Wen, P. Y. (2005) Targeted molecular therapy of malignant gliomas. Curr. Neurol. Neurosci. Rep. 5, 186-197.
58. Kilic, T., Alberta, J. A., Zdunek, P. R., Acar, M., Iannarelli, P., O'Reilly, T., Buchdunger, E., Black, P. M., Stiles, C. D. (2000) Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 60, 5143-5150.
59. Kimura, K., Ito, M., Amano, M., Chihara, K., Fukata, Y., Nakafuku, M., Yamamori, B., Feng, J., Nakano, T., Okawa, K., Iwamatsu, A., Kaibuchi, K. (1996) Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 273, 245-248.
60. Kitamura, Y., Go, S., Hatanaka K. (1978) Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 52, 447-452.
61. Kitamura, Y., Hirota, S., Nishida, T. (2003) Gastrointestinal stromal tumors (GIST): a model for molecule-based diagnosis and treatment of solid tumors. Cancer Sci. 94, 315-320. Erratum in: Cancer Sci. 94, 930.
62. Knight, Z. A., Shokat, K. M. (2005) Features of selective kinase inhibitors. Chem. Biol. 12, 621-637.
63. Knighton, D. R., Zheng, J. H., Ten Eyck, L. F., Ashford, V. A., Xuong, N. H., Taylor, S. S. Sowadski, J. M. (1991) Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253, 407-414.
64. Kondapalli, L., Soltani, K., Lacouture, M. E. (2005) The promise of molecular targeted therapies: protein kinase inhibitors in the treatment of cutaneous malignancies. J. Am. Acad. Dermatol. 53, 291-302.
65. Kralovics, R., Passamonti, F., Buser, A, S., Teo, S. S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., Skoda, R. C. (2005) A gain of function mutations of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779-1790.
66. Krause, D. S., Van Etten, R. A. (2005) Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353, 172-187.
67. Kuan, C. Y., Yang, D. D., Samanta Roy, D. R., Davis, R. J., Rakic, P., Flavell, R. A. (1999) The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron 22, 667-676.
68. Kwak, E. L., Sordella, R., Bell, D. W. (2005) Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. USA 102, 7665-7670.
69. Lantieri, F., Griseri, P., Ceccherini, I. (2006) Molecular mechanisms of RET-induced Hirschsprung pathogenesis. Ann. Med. 38, 11-19.
70. Leonard, W. J. (1996) Dysfunctional cytokine receptor signaling in severe combined immunodeficiency. J. Invest. Med. 44, 304-311.
71. Leonard, W. J., O'Shea, J. J. (1998) Jaks and STATs: biological implications. Annu. Rev. Immunol. 16, 293-322.
72. Leung, T., Chen, X. Q., Manser, E., Lim, L. (1996) The p160 RhoA-binding kinase ROK is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol. Cell Biol. 16, 5313-5327.
73. Lew, D. J., Burke, D. J. (2003) The spindle assembly and spindle position checkpoints. Annu. Rev. Genet. 37, 251-282.
74. Liew, R., Macleod, K. T., Collins, P. (2003) Novel stimulatory actions of the phytoestrogen genistein: effects on the gain of cardiac excitation-contraction coupling. FASEB J. 17, 1307-1309.
75. Linnekin, D. (1999) Early signaling pathways activated by c-kit in hematopoietic cells. Int. J. Biochem. Cell. Biol. 31, 1053-1074.
76. Liu, J., Kipreos, E. T. (2000) Evolution of cyclin-dependent kinases (CDKs) and CDK-activating kinases (CAKs): differential conservation of CAKs in yeast and metazoa. Mol. Biol. Evol. 17, 1061-1074.
77. Loirand, G., Guerin, P., Pacaud, P. (2006) Rho kinases in cardiovascular physiology and pathophysiology. Circ. Res. 98, 322-334.
78. Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A., Das, J., Doweyko, A. M., Fairchild, C., Hunt, J. T., Inigo, I., Johnston, K., Kamath, A., Kan, D., Klei, H., Marathe, P., Pang, S., Peterson, R., Pitt, S., Schieven, G. L., Schmidt, R. J., Tokarski, J., Wen, M. L., Wityak, J., Borzilleri, R. M. (2004) Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2- hydroxyethyl)-piperazin-2-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658-6661.
79. Lowery, D. M., Lim, D., Yaffe, M. B. (2005) Structure and function of Polo-like kinases. Oncogene 10, 248-259.
80. Lugo, T. G., Witte, O. N. (1989) The BCR-ABL oncogene transforms Rat-1 cells and cooperates with c-myc. Mol. Cell Biol. 9, 1263-1270.
81. Lynch, T., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., Louis, D. N., Christiani, D. C., Settleman, J., Haber, D. A. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139.
82. Mackarehtschian, K., Hardin, J. D., Moore, K. A., Boast, S., Goff, S. P., Lemischka, I. R. (1995) Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 3, 147-161.
83. Madhusudan, S. and Ganesan, T. S. (2004) Tyrosine kinase inhibitors in cancer therapy. Clin. Biochem. 37, 618-635.
84. Maeda, H., Yamagata, A., Nishikawa, S., Yoshinaga, K., Kobayashi, S., Nishi, K., Nishikawa, S. (1992) Requirement of c-kit for development of intestinal pacemaker system. Development 116, 369-375.
85. Manning, G., Whyte, D. B., Martinez, R., Hunter, T., Sudarsanam, S. (2002) The protein kinase complement of the human genome. Science 298, 1912-1934.
86. McInnes, C., Mezna, M., Fischer, P. M. (2005) Progress in the discovery of polo-like kinase inhibitors. Curr. Top. Med. Chem. 5, 181-197.
87. McNiece, I. K., Briddell, R. A. (1995) Stem cell factor. J. Leukocyte Biol. 58, 14-22.
88. Mendoza, F. J., Espino, P. S., Cann, K. L., Bristow, N., McCrea, K., Los, M. (2005) Anti-tumor chemotherapy utilizing peptide-based approaches - apoptotic pathways, kinases, and proteasome as targets. Arch. Immunol. Ther. Exp. (Warsz.) 53, 47-60.
89. Mora, A., Komander, D., van Aalten, D. M., Alessi, D. (2004) PDK1, the master regulator of AGC kinase signal transduction. Semin. Cell Dev. Biol. 15, 161-170.
90. Moretti, S., Macchiarulo, A., De Falco, V., Avenia, N., Barbi, F., Carta, C., Cavaliere, A., Melillo, R. M., Passeri, L., Santeusanio, F., Tartaglia, M., Santoro, M., Puxeddu, E. (2006) Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma. Oncogene. Epub, Feb. 27.
91. Morrison, D. K. (2004) Cancer: enzymes play molecular tag. Nature 428, 813-815.
92. Mueller, B. K., Mack, H., Teusch, N. (2005) Rho kinase, a promising drug target for neurological disorders. Nat. Rev. Drug. Discov. 4, 387-398.
93. Nakagawa, O., Fujisawa, K., Ishizaki, T., Saito, Y., Nakao, K., Narumiya, S. (1996) ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett. 392, 189-193.
94. Nakatani, H., Kobayashi, M., Jin, T., Taguchi, T., Sugimoto, T., Nakano, T., Hamada, S., Araki, K. (2005) STI571 (Glivec) inhibits the interaction between c-kit and heat shock protein 90 of the gastrointestinal stromal tumor cell line, GIST-T1. Cancer Sci. 96, 116-119.
95. Nocka, K., Tan, J. C., Chiu, E., Chu, T. Y., Ray, P., Traktman, P., Besmer P. (1990) Molecular bases of dominant negative and loss of function mutation at the murine c-kit/white spotting locus: W37, Wv, W41 and W. EMBO J. 9,1805-1813.
96. Ogilvie, J. B., Kebebew, E. (2006) Indication and timing of thyroid surgery for patients with hereditary medullary thyroid cancer syndromes. J. Natl. Compr. Canc. Netw. 4, 139-147.
97. Pauletto, P., Sartore, S., Pessina, A. C. (1994) Smooth muscle cell proliferation and differentiation in neointima formation and vascular restenosis. Clin. Sci. 87, 467-479.
98. Pendergast, A. M. (2002) The Abl family kinases: mechanisms of regulation and signaling. Adv. Cancer Res. 85, 51-100.
99. Plattner, R., Koleske, A. J., Kazlauskas, A., Pendergast, A. M. (2004) Bidirectional signaling links the Abelson kinases to the platelet-derived growth factor receptor. Mol. Cell Biol. 24, 2573-2583.
100. Poole, D. P., Van Nguyen, T., Kawai, M., Furness, J. B. (2004) Protein kinases expressed by interstitial cells of Cajal. Cell Biol. 121, 21-30.
101. Raizer, J. J. (2005) HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. J. Neurooncol. 74, 77-86.
102. Rattan, R., Giri, S., Singh, A. K., Singh, I. (2005) Rho/ROCK pathway as a target of tumor therapy. J. Neurosci. Res. 83, 243-255.
103. Ready, N. (2005) Inhibition of the epidermal growth factor receptor (EGFR) in combined modality treatment for locally advanced non-small cell lung cancer (NSCLC). Semin. Oncol. 32 (Suppl. 3), S35-41.
104. Ren, S., Rollins, B. J. (2004) Cyclin C/cdk3 promotes Rb-dependent G0 exit. Cell 117, 239-251.
105. Rosnet, O., Marchetto, S., deLapeyriere, O., Birnbaum, D. (1991) Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/ CSF1R family. Oncogene 6, 1641-1650.
106. Ross, R. (1995) Growth regulatory mechanisms and formation of the lesions of atherosclerosis. Ann. N. Y. Acad. Sci. 748, 1-4.
107. Roumiantsev, S., Krause, D. S., Neumann, C. A., Dimitri, C. A., Asiedu, F., Cross, N. C., Van Etten, R. A. (2004) Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell 5, 287-298.
108. Russell, E. S. (1979) Hereditary anemias of the mouse: a review for geneticists. Adv. Genet. 20, 357-459.
109. Saharinen, P., Alitalo, K. (2003) Double target for tumor mass destruction, J. Clin. Invest. 111, 1277-1280.
110. Sattler, M., Salgia, R. (2004) Targeting c-kit mutations: basic science to novel therapies. Leuk. Res. 28 (Suppl. 1), S11-20.
111. Sausville, E. A. (2002) Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol. Med. 8 (Suppl. 4), S32-37.
112. Savage, D. G., Antman, K. H. (2002) Imatinib mesylate - a new oral targeted therapy. N. Engl. J. Med. 346, 683-693.
113. Shimada, M., Kitamura, Y., Yokoyama, M., Miyano, Y., Maeyama, K., Yamatodani, A., Takahashi, Y., Tatsuta, M. (1980) Spontaneous stomach ulcer in genetically mast cell depleted W/Wv mice. Nature 293, 662-664.
114. Schang, L. M. (2004) Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication. Biochim. Biophys. Acta 1697, 197-209.
115. Schang, L. M. (2005) Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs. Curr. Drug Targets Infect. Disord. 5, 29-37.
116. Schang, L. M., Bantly, A., Schaffer, P. A. (2002) Explant-induced reactivation of herpes simplex virus occurs in neurons expressing nuclear cdk2 and cdk4. J. Virol. 76, 7724-7735.
117. Schlessinger, J. (2000) Cell signaling by receptor tyrosine kinases. Cell 13, 211-225.
118. Sommer, G., Agosti, V., Ehlers, I., Rossi, F., Corbacioglu, S., Farkas, J., Moore, M., Manova, K., Antonescu, C. R., Besmer, P. (2003) Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proc. Natl. Acad. Sci. USA 100, 6706-6711.
119. Sordella, R., Bell, D. W., Haber, D. A., Settleman, J. (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163-1167.
120. Stamos, J., Sliwkowski, M. X., Eigenbrot, C. (2002) Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277, 46265-46272.
121. Sumi, T., Matsumoto, K., Nakamura, T. (2001) Specific activation of LIM kinase 2 via phosphorylation of threonine 505 by ROCK, a Rho-dependent protein kinase. J. Biol. Chem. 276, 670-676.
122. Tatsuka, M., Sato, S., Kitajima, S., Suto, S., Kawai, H., Miyauchi, M., Ogawa, I., Maeda, M., Ota, T., Takata, T. (2004) Overexpression of Aurora-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis (2005) Oncogene 24, 1122-1127.
123. Thomis, D. C., Berg, L. J. (1997) Peripheral expression of Jak3 is required to maintain T lymphocyte function. J. Exp. Med. 185, 197-206.
124. Thommes, K., Lennartsson, J., Carlberg, M., Ronnstrand, L. (1999) Identification of Tyr-703 and Tyr-93 6 as the primary association sites for Grb2 and Grb7 in the c-kit/stem cell factor receptor. Biochem. J. 341, 211-216.
125. Thumkeo, D., Keel, J., Ishizaki, T., Hirose, M., Nonomura, K., Oshima, H., Oshima, M., Taketo, M. M., Narumiya, S. (2003) Targeted disruption of the mouse Rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death. Mol. Cell. Biol. 23, 5043-5055.
126. Tian, Q., Frierson, H. F. Jr., Krystal, G. W., Moskaluk, C. A. (1999) Activating c-kit gene mutations in human germ cell tumors. Am. J. Pathol. 154, 1643-1647.
127. Tighe, A., Johnson, V. L., Albertella, M., Taylor, S. S. (2001) Aneuploid colon cancer cells have a robust spindle checkpoint. EMBO Rep. 2, 609-614.
128. Tort, F., Hernandez, S., Bea, S., Camacho, E., Fernandez, V., Esteller, M., Fraga, M. F., Burek, C., Rosenwald, A., Hernandez, L., Campo, E. (2005) Checkpoint kinase 1 (CHK1) protein and mRNA expression is downregulated in aggressive variants of human lymphoid neoplasms. Leukemia 19, 112-117.
129. Traxler, P., Bold, G., Buchdunger, E., Caravatti, G., Furet, P., Manley, P., O'Reilly, T., Wood, J., Zimmermann, J. (2001) Tyrosine kinase inhibitors: from rational design to clinical trials. Med. Res. Rev. 21, 499-512.
130. Traxler, P., Furet, P., Mett, H., Buchdunger, E., Meyer, T., Lydon, N. B. (1996) 4-(phenylamino) pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. J. Med. Chem. 39, 2285-2292.
131. Uckun, F. M., Mao, C. (2004) Tyrosine kinases as new molecular targets in treatment of inflammatory disorders and leukemia. Curr. Pharm. Des. 10, 1083-1091.
132. Vallbohmer, D., Lenz, H. J. (2005) Epidermal growth factor receptor as a target for chemotherapy. Clin. Colorectal Cancer 5 (Suppl. 1), S19-27.
133. Van Etten, R. A. (1999) Cycling, stressed-out and nervous: cellular functions of c-Abl. Trends Cell. Biol. 9, 179-186.
134. Verweij. J. (2004) KIT and PDGF as targets. Cancer Treat. Res. 120, 117-27.
135. Villalba, M., Altman, A. (2002) Protein kinase C-θ (PKC θ), a potential drug target for therapeutic intervention with human T cell leukemias. Curr. Cancer Drug Targets 2, 125-137.
136. Villalba, M., Bushway, P., Altman, A. (2001) Protein kinase C-θ mediates a selective T cell survival signal via phosphorylation of BAD. J. Immunol. 166, 5955-5963.
137. Waetzig, V., Herdegen, T. (2005) Context-specific inhibition of JNKs: overcoming the dilemma of protection and damage. Trends Pharmacol. Sci. 26, 455-461.
138. Warmuth, M., Damoiseaux, R,, Liu, Y., Fabbro, D., Gray, N. (2003) SRC family kinases: potential targets for the treatment of human cancer and leukemia. Curr. Pharm. Des. 9, 2043-2059.
139. Wong, S., McLaughlin, J., Cheng, D., Zhang, C., Shokat, K. M., Witte, O. N. (2004) Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations. Proc. Natl. Acad. Sci. USA 101, 17456-17461.
140. Yang, D. D., Conze, D., Whitmarsh, A. J., Barrett, T., Davis, R. J., Rincon, M., Flavell, R. A. (1998) Differentiation of CD4C T cells to Th1 cells requires MAP kinase JNK2. Immunity 9, 575-585.
141. Yarden, Y., Escobedo, J. A., Kuang, W. J., Yang-Feng, T. L., Daniel, T. O., Tremble, P. M., Chen, E. Y., Ando, M. E., Harkins, R. N., Francke, U. (1986) Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature 323, 226-232.
142. Yokoyama, M., Tatsuta, M., Baba, M., Kitamura, Y. (1982) Bile reflux: a possible cause of stomach ulcer in nontreated mutant mice of W/Wv genotype. Gastroenteology 82, 857-863.
143. Zhang, P., Gao, W. Y., Turner, S., Ducatman, B. S. (2003) Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Mol. Cancer 2, 1.
144. Zhou, H., Kuang, J., Zhong, L., Kuo, W. L., Gray, J. W., Sahin, A., Brinkley, B. R., Sen, S. (1998) Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat. Genet. 20, 189-193.